Home > Gastroenterology > ECCO 2022 > Short-Term and Long-Term Treatment Results > VEDOKIDS: Vedolizumab seems effective in paediatric IBD

VEDOKIDS: Vedolizumab seems effective in paediatric IBD

Presented By
Dr Dan Turner, Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition, Israel
Conference
ECCO 2022
Trial
VEDOKIDS
Vedolizumab induction therapy was effective in paediatric participants with inflammatory bowel disease (IBD). The prospective, multicentre VEDOKIDS study also showed that disease severity at baseline might predict the response to vedolizumab in this population. Since data on the use of vedolizumab in children with IBD are limited, this study helps to understand the applicability of this agent in paediatric patients with IBD. The VEDOKIDS study (NCT02862132), a prospective cohort study, included 142 children (0–18 years) with Crohn’s disease (CD; n=65) or ulcerative colitis (UC; n=77), of whom approximately 68% had failed on previous anti-TNF treatment [1]. The participants were exposed to intravenous vedolizumab 177 mg/m2 Body Surface Area (BSA) up to a maximum of 300 mg at weeks 0, 2, 6 and then every 8 weeks. Clinical remission, defined as st...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on